Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 1997

View Archived Issues

Allergan expects lower first-half earnings

RPR seeks FDA approval for new indications for Lovenox

Pharmacia & Upjohn prepares stereoisomers of FCE-28260

SCRAS describes galanthamine derivatives

5-HT1A antagonists from American Home Products

Glaxo Wellcome discloses cGMP-PDE inhibitors

Dual NOS/COX inhibitors claimed by SCRAS

New salts of known antimigraine agent from Glaxo Wellcome

Bay-x-3702: Neuroprotective 5-HT1A receptor agonist from Bayer

RCT patents compounds for acne and other skin infections

First clinical trial results reported for MEDI-493

New formulation of podofilox receives FDA approval

New drug therapy for erectile dysfunction more effective than PGE1

FDA reviews Wyeth-Ayerst combination vaccine

Savage introduces nonhalogenated corticosteroid

CytoTAb shows potential for use in the treatment of malaria

Promising clinical results for CollaGenex's Periostat

New advances in Alzheimer's disease treatment, prevention and diagnosis

CPMP approves lepirudin

Vitrasert receives European marketing clearance

Atrix presents Atridox phase III results

Dainippon presents broad-spectrum antiemetic agent

New antiinflammatory agent from Yakult Honsha

Aprogenex and Centocor sign licensing agreement

Fujisawa describes compound for autoimmune diseases

Diagnostic Products Corporation initiates European marketing of pancreatic cancer diagnostic

Santen characterizes dual NEP/ACE inhibitor

Phase III results reported on finasteride for male pattern hair loss

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...